Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Centessa Pharmaceuticals (NASDAQ:CNTA) and raises the price target from $9 to $10.
August 15, 2023 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim maintains a Buy rating on Centessa Pharmaceuticals and raises the price target from $9 to $10. This could potentially lead to an increase in the stock's price.
The raised price target by Guggenheim indicates a positive outlook for Centessa Pharmaceuticals. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100